U.S. stocks closed higher on Friday, with the Nasdaq setting another record as investors cheered major earnings reports.» Read More
Shortly after Eli Lilly reported way better than expected earnings this morning, Amylin Pharmaceuticals fired a new salvo in its escalating proxy battle with billionaire activist investor Carl Icahn.
Stocks ended a rocky session higher Thursday as investors were encouraged by JPMorgan's results and techs rallied amid anticipation of better results from Google after the bell.
An early pop fizzled Thursday as investors digested a mixed bag of economic and earnings news. Banks were mixed as techs gained.
Futures pointed to a higher open Thursday as investors shrugged off some dismal data points, choosing to focus on a drop in the headline jobless-claims number.
JPMorgan Chase could rule the day Thursday. Traders expect the stock and Treasury markets to take their cue from the bank's first quarter earnings report and forward comments.
Following are the “Fast & Furious” trades - hot ways to play tomorrow's market moving events.
Investors are eager to hear results from Amylin and Biogen, Thursday. It seems the future of both firms could lie in the hands of Fast Money friend Carl Icahn!
Eric writes, “I know Karen likes some of the names in biotech. Would she be a buyer of Biogen ahead of earnings this week?”
After a five-week rally, stocks face one of their toughest challenges yet - a very nasty earnings season.
Once again, activist investor Carl Icahn turns to Fast Money to set the record straight on all the rumors surrounding his wheeling and dealing.
Following are the day’s biggest winners and losers. Find out why shares of Biogen and Brinker International popped while Exxon Mobil and MGM Mirage dropped.
Stock and options traders are piling into Biogen Idec on speculation that the drug maker could be a takeover target. About 75,000 options contracts traded on the name, more than 10 times the average over the last 20 session...
Which companies are looking like top takeover targets, right now? Jon Najarian has spotted hot options action in three stocks!
The Pit Boss is seeing explosive options action in a drug stock. Find out which one!
Cougar Biotech has a drug in its pipeline that could offer big help to patients with this disease.
The IBB biotech ETF is drawing strong options activity Thursday, as news ranging from mergers to government regulation continues to rock the sector.
Even though nearly every analyst this morning is saying Thursday's bloodbath was an overreaction, investors are continuing to sell biopharma stocks in the early going Friday.
Rob Morgan of Clermont Wealth Strategies got some encouragement from President Obama's remarks about stimulus and recovery, but not enough to make him bullish on financials. That's not to say he's completely down on stocks.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
The Dow rallied for a second day on Friday on hopes Washington's stimulus package and a bank rescue plan will bolster the ailing economy.